An analytical quantification clinical research, and an observational descriptive qualitative pharmacological research analysis on pharmacovigilance assessments of metformin monotherapy and combination therapies: A mixed-method study

ABSTRACT

Background: The anti-diabetic mono- as well as combination pharmacotherapy with metformin, for the routine healthcare treatment of type II diabetic patients, is sufficiently efficacious, with an adequately safe glycemic stabilization rate. This pharmacotherapeutic property of metformin has resulted in metformin being a widely used first-line oral hypoglycemic drug, among different types of diabetic patients. Aims and Objectives: The objective of this mixed-method research study was an analytical quantification clinical research, and an observational descriptive qualitative pharmacological research analysis, on the pharmacovigilance assessments of metformin. Materials and Methods: This study procedure was a was a multivariate, observational, descriptive, retrospective, qualitative, pharmacological research analysis study, and, a multivariate, multicenter, analytical quantification of global clinical research study literature databases on pharmacovigilance assessments of metformin, among type II anti-diabetic patients. A multivariate evidence-based pharmacological research study was done, for a comparative quantification analysis between the qualitative pharmacovigilance studies on metformin monotherapy and combination therapies, and the quantitative pharmacovigilance studies on metformin monotherapy and combination therapies, conducted within a span of the past 5 years. This study was conducted, by recording, calculating, statistically deriving the percentage of the differential quantitative analysis, retrieved from the medical study literature database, along with a statistical interpretative analysis and the subsequent graphical representation of the deduced study results. Results: In this mixed method quantitative and qualitative research study, it was deduced from these study results, that slightly more qualitative pharmacovigilance assessment studies, that is 53%, were conducted on metformin monotherapy and combination therapies, than quantitative pharmacovigilance assessment studies, that is 47%, on metformin monotherapy and combination therapies; and both were analyzed with evidence-based details. Conclusion: This research study provided a comprehensive pharmacovigilance assessment of metformin monotherapy and combination therapies.